Mutations and biomarkers

HER2-positive colorectal cancer: what it means and which targeted treatments exist

What does it mean that my colon cancer is HER2-positive?

3 min read Updated: 02/11/2026 Reviewed by: Equipo CRC Warriors Last reviewed: 02/11/2026

In short

Between 3 % and 5 % of colorectal cancers have too many copies of the HER2 gene, mostly RAS wild-type tumours. It is uncommon, but it matters: there are HER2-targeted treatments (trastuzumab with tucatinib, trastuzumab deruxtecan) with good results in previously treated patients, and anti-EGFR antibodies work less well in these tumours.

In this guide
  1. What HER2 is
  2. How it is determined
  3. Why it changes treatment
  4. HER2-targeted treatments
  5. Access in Spain
  6. What to ask at your appointment

What HER2 is

HER2 is a protein on the cell surface that works as a growth antenna. It is best known from breast cancer, but it also appears in other tumours. In colorectal cancer, 3-5 % of cases have the HER2 gene amplified (too many copies) or the protein overexpressed. It is more common in RAS and BRAF wild-type tumours (without a mutation) and in the left colon and rectum; among RAS wild-type tumours the figure rises to 5-8 %.

It is not hereditary: it is an alteration acquired by the tumour.

How it is determined

  • Immunohistochemistry (IHC): stains the protein in the tumour tissue and gives a score from 0 to 3+. A 3+ result is considered positive.
  • FISH / ISH: counts the gene copies. It is used to confirm 2+ (borderline) cases.
  • NGS panel: detects the amplification together with the other alterations (RAS, BRAF, MSI…). This is now the most common route in hospitals running broad panels.

European and American guidelines recommend testing HER2 in every patient with RAS wild-type metastatic disease. If your molecular report does not mention it, ask.

Why it changes treatment

  • Anti-EGFR antibodies (cetuximab, panitumumab) work less well when HER2 is amplified, even if the tumour is RAS wild-type. That is why it is worth knowing before starting.
  • There are HER2-targeted therapies that have shown responses in patients who had already received chemotherapy.

HER2-targeted treatments

CombinationWhat it isEvidence
Trastuzumab + tucatinibIntravenous antibody + tabletMOUNTAINEER study: responses in close to 40 % of previously treated RAS wild-type patients, with long durations. Approved in the United States (2023); access in Europe varies.
Trastuzumab deruxtecan (T-DXd)Antibody linked to a chemotherapy that is released inside the cellDESTINY-CRC01 study: responses around 45 % in IHC 3+ tumours. Risk of pneumonitis (lung inflammation), which means watching for cough or breathlessness and reporting it immediately.
Trastuzumab + pertuzumab or + lapatinibTwo antibodies, or antibody + tabletPhase II studies (MyPathway, HERACLES) with responses around 30 %. These are the older combinations.

These are treatments without classic chemotherapy (apart from the payload carried by T-DXd), with different side effects: diarrhoea and skin problems (tucatinib), nausea and low blood counts (T-DXd), and heart monitoring (echocardiogram) with all of them.

Access in Spain

None of these combinations yet has a broad funded indication for colon cancer in Spain; the usual route is a clinical trial, an access programme or an individual request by the hospital. If your tumour is HER2-positive, ask your team to look for open trials (our guided trial finder lets you filter by HER2) and to consider referral to a centre with active studies.

What to ask at your appointment

  • Has HER2 been tested in my tumour? By IHC, FISH or NGS, and what was the result?
  • Am I RAS and BRAF wild-type? Does that change the plan if HER2 is amplified?
  • Is there any trial with anti-HER2 drugs I could join, here or at another hospital?
  • If an anti-EGFR is proposed, has HER2 been taken into account?
  • What heart and lung monitoring would I need with these drugs?

Frequently asked questions

Is HER2-positive colon cancer the same as in breast cancer?

The alteration is the same (amplification of the HER2 gene) and similar drugs are used, but it is far less common in colon cancer (3-5 % versus 15-20 % in breast cancer) and the treatments are less established: in colon cancer most of the evidence is in previously treated patients and access is usually through a trial.

Can I receive cetuximab or panitumumab if I am HER2-positive?

You can, but the chance that they work is lower. Guidelines suggest taking this into account when choosing first-line treatment and, where possible, prioritising a trial with anti-HER2 therapy or chemotherapy with bevacizumab.

What are the side effects of trastuzumab deruxtecan?

The most common are nausea, tiredness and low blood counts. The most important is pneumonitis (lung inflammation), which occurs in around 1 in 10 patients: any new cough, fever or breathlessness should be reported the same day.

Next step

What can you do now?

We will let you know when there is news

No account needed: just your email. One weekly email, only when there is something new. Unsubscribe in one click.

Sources · 5 sources consulted
  1. ESMO Clinical Practice Guideline — Metastatic colorectal cancer (2023)
  2. Strickler JH et al. Tucatinib plus trastuzumab for HER2-positive metastatic colorectal cancer (MOUNTAINEER). Lancet Oncol 2023
  3. Siena S et al. Trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer (DESTINY-CRC01). Lancet Oncol 2021
  4. NCCN Guidelines for Patients — Colon Cancer
  5. SEOM — Cáncer de colon y recto

Reviewed by: Equipo CRC Warriors · Last reviewed: 02/11/2026.
This guide is general information prepared by the CRC Warriors Association (non-profit) from public sources. It does not replace the assessment of your medical team or professional advice on your specific case. If you spot an error, write to contacto@crcwarriors.org.

This guide is free thanks to members and donors

We write it and keep it up to date as a non-profit patient association. If it helped you, help us write the next one.